Who are ACEI / ARB+finerenone's main competitors?

No direct comparators detected in our index.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/acei-arb-finerenone.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

ACEI / ARB+finerenone — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

ACEI / ARB+finerenone (ACEI / ARB+finerenone) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination. Area: Cardiovascular / Nephrology.

marketed ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor Cardiovascular / Nephrology Small molecule Live · refreshed every 30 min

Target snapshot

ACEI / ARB+finerenone (ACEI / ARB+finerenone) — Capital Institute of Pediatrics, China. This combination therapy blocks angiotensin II signaling via ACE inhibitors or ARBs while finerenone acts as a non-steroidal mineralocorticoid receptor antagonist to reduce kidney and cardiovascular injury.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
ACEI / ARB+finerenone TARGET	ACEI / ARB+finerenone	Capital Institute of Pediatrics, China	marketed	ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination	Angiotensin-converting enzyme / Angiotensin II type 1 receptor + Mineralocorticoid receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (ACE inhibitor / ARB + non-steroidal mineralocorticoid receptor antagonist combination class)

Capital Institute of Pediatrics, China · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ACEI / ARB+finerenone — Competitive Intelligence Brief. https://druglandscape.com/ci/acei-arb-finerenone. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab